NeurAxis reports 150% revenue growth for its IB-Stim nerve stimulation device
Third-quarter sales of the pediatric abdominal pain neuromodulation device reached about $2.0 million, helped by a new procedure code and wider insurance coverage. Losses also grew.
NeurAxis reported third-quarter revenue of about $2.0 million on November 9, up 150% from $0.8 million a year earlier. The Indiana company sells IB-Stim, a percutaneous electrical nerve field stimulation (PENFS) device that is FDA-cleared for functional abdominal pain linked to irritable bowel syndrome, and a pediatric guideline now recommends it for that use. Unit deliveries rose 92%. The net loss widened to $6.5 million, including $4.3 million in one-time stock compensation charges, and cash fell to $4.5 million.
The company credits a dedicated CPT billing code that took effect in January and new insurer policies it says now cover more than 147 million people. It also lists an FDA clearance for abdominal pain in functional dyspepsia in patients aged 8 and older. Figures are company-reported.